



The Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T (RAPID-TnT) Study

Derek P Chew, MBBS MPH PhD, Kristina Lambrakis BSc, Andrew Blyth MBChB PhD, Anil Seshadri MBBS, Michael JR Edmonds MBBS, Tom Briffa PhD, Louise A Cullen MBBS PhD, Stephen Quinn PhD, Jonathan Karnon PhD, Anthony Chuang MBBS, Adam J Nelson MBBS, Deborah Wright MNSc, Matthew Horsfall RN, Erin Morton PhD, John K. French MBChB PhD, Cynthia Papendick MBBS



Declaration of interest

- Others (Grant in Aid Roche Diagnostics)



BACKGROUND

- ⚡ Suspected ACS in the Emergency Department
 - one of the most common presentations to emergency services
 - very resource intensive
 - equivocal benefit for the traditional 'liberal' approach to further testing
- ⚡ High sensitivity troponins have the potential to improve the early diagnosis of myocardial infarction
 - High negative predictive value effective in ruling out MI.
- ⚡ Increased sensitivity could lead to more downstream cardiac testing
 - Uncertain benefit and even potential harm.

KEY STUDY QUESTION

- ❖ What is the clinical impact of the **improved diagnostic precision** of hs-cTnT assay incorporated into a rapid 0/1-hour protocol in terms of **patient outcomes** and/or **greater emergency department efficiency** when embedded within practice?
 - **Conditions needed to address this question:**
 1. No prior access to hs-cTnT results to influence clinical decision-making
 2. Clinical practice where 0/1-hour protocols are not standard of care
- ❖ **Primary Hypothesis:** Compared with our current standard practice, clinical care based on a 0/1-hour hs-cTnT protocol will provide non-inferior clinical outcomes at 30 days
- ❖ **Secondary hypothesis:** Suspected ACS patients discharged from the ED under the 0/1-hour hs-cTnT protocol is safe (**30-day death or new/recurrent MI of <1%**)

STUDY DESIGN

- Prospective “in practice” patient-level randomized non-inferiority evaluation of a **0/1-hour protocol** using a **hs-cTnT** reporting format (LoD 5ng/L) compared with a **0/3-hour protocol** using **masked hs-cTnT** reporting ($\leq 29\text{ng/L}$) in participants with suspected ACS
- Conducted in four metropolitan public emergency departments in Adelaide, Australia from August 2015-April 2019
- **Funding:** National Health and Medical Research Council of Australia (APP 1224471) and restricted educational grant from Roche Diagnostics International (Rotkreuz, Switzerland)

RAPID TnT: OUTCOME MEASURES

The primary outcome: the 30-days composite endpoint of:

- All-cause mortality
- Myocardial infarction adjudicated by the 4th Universal Definition of MI

***Excluding Index “presenting” MI**


Major secondary clinical outcomes:

- The occurrence of all-cause mortality or new ACS at 12 months
- Cardiovascular mortality at 30 days and 12 months
- Unplanned hospital admission: non-elective coronary revascularization; CVA; atrial or ventricular arrhythmias; CCF without MI; as documented by a hospital discharge summary at 30 days and 12 months.


LOCAL IMPLEMENTATION OF TROPONIN T

- ✦ In 2011 Roche Diagnostics 5th generation hs-cTnT assay was introduced as the **sole troponin assay** in public hospitals in South Australia
- ✦ Due to concerns regarding a higher rate of abnormal troponin results and increased invasive testing, the **reported lower limit was aligned to the 4th generation level** of ≤ 29 ng/L.
 - (N.B: an improvement in test performance recognized)
- ✦ Local EDs remained masked to troponin T concentration below 29 ng/L; and clinicians had no prior clinical experience with hs-cTnT results below this level

Staged Implementation of cTnT to hs-cTnT



RAPID TnT: STUDY SCHEMATIC



RAPID TnT: ELIGIBILITY CRITERIA



Inclusion Criteria

Patients presenting to the ED were eligible if they had:

- Clinical features of chest pain or suspected ACS as the principal cause for investigation;
- Baseline electrocardiogram (ECG) interpreted as not definitive for coronary ischemia;
- Age greater than 18 years of age or older;




Exclusion Criteria


Patients were considered ineligible if they:

- Require admission for non-chest pain related reasons;
- Presented as a result of a transfer from another hospital;
- Are representing with chest pain within 30 days of last presentation;
- Require permanent dialysis;
- Are unable to complete clinical history questionnaires due to language or comorbidity;



STANDARD 0/3-HOUR masked hs-cTnT PROTOCOL



0/1-HOUR hs-cTnT PROTOCOL



RAPID TnT: SYSTEMATIZED DATA COLLECTION


-  Leverage single state-wide patient administration system and pathology systems through data-linkage
 - All hs-cTnT results (index and subsequent) sourced from the pathology service
 - All representations to the ED/hospitals interrogated
 - All ECG, cardiac investigation reporting systems interrogated
-  Index admission and subsequent event adjudication:
 - All episodes of care with at least 1 hs-cTnT result >14ng/L examined
 - All episodes of care with targeted ICD-10AM and DRG codes examined

RAPID TnT: STATISTICAL CONSIDERATIONS

- ⚡ **Sample size** targeted 1212 patients receiving a rule out-MI/discharge recommendation in the 0/1 hour arm to assess primary endpoint (97.5% C.I.) event rate of <1%
 - Anticipated rate of rule out MI recommendation was 60% (observed 72%)
 - Anticipated rate of initial troponin >29ng/L was 25% (observed rate 9%). Planned sample n=5400
- ⚡ **Non-inferiority margin** defined as upper 97.5% C.I. of 0/1 hour hs-cTnT arm not 0.5% worse than 0/3-hour masked hs-cTnT arm i.e. Number needed to harm with new protocol >200
- ⚡ **Primary analysis:** Poisson regression with robust standard errors using ITT population
 - **Key Sub-analysis:** patients with *initial troponin* ≤ 29 ng/L
- ⚡ **Sensitivity analysis:** Poisson regression using PP population, defined as troponin reported as randomized and care aligned with recommendation
- ⚡ April 2019, DSMB informed the Steering Committee that there is no longer equipoise regarding the event rate in patients with Rule-out MI recommendation. Study stopped

RAPID-TnT

Consort Diagram





BASELINE CHARACTERISTICS

Characteristic	Standard (n = 1642)	0/1-Hour (n = 1646)
Age, median (IQR)	58.6 (48.8, 71.2)	58.7 (48.6, 69.4)
Female sex	46.8 %	46.8 %
Hypertension	20.5 %	19.7 %
Diabetes	17.4 %	15.8 %
Dyslipidaemia	44.0 %	43.3 %
Current smoker	35.6 %	34.6 %
Prior history of CAD	29.0 %	27.8 %
Prior coronary artery bypass grafting	2.8%	3.0 %
Prior percutaneous coronary intervention	8.4%	10.4 %
Glomerular filtration rate, ml/min/1.73m ² , median (IQR)	86.0 (71.1, 98.1)	86.2 (71.6, 98.2)
EDACS, median (IQR)	15.0 (9.0, 21.0)	14.0 (9.0, 20.0)
GRACE score, median (IQR)	75.0 (56.1, 100.8)	74.1 (55.2, 97.2)
HEART score, median (IQR)	3.0 (2.0, 4.0)	3.0 (2.0, 4.0)




TIME BETWEEN TROPONIN T TESTING






TRIAGE RECOMMENDATION





N.B.: Actual management based on clinical discretion



INDEX CLINICAL DIAGNOSIS


All participants





PRIMARY ENDPOINT: 30-day Death or MI


All-cause Death or MI (%)



IRR: 1.06 (95% C.I.: 0.53-2.11)
Non-inferiority p=0.006
Log-rank p-value =0.886

*IRR=Incident rate ratio
Poisson confidence intervals


Standard	1642	1635	1633	1628	1626
0/1-Hour	1646	1637	1634	1631	1629



CV RE-HOSPITALIZATION

30-day rehospitalization for non-elective coronary revascularization, heart failure, CVA and arrhythmias

CV Rehospitalization (%)



IRR: 1.53 (95% C.I.: 1.12-2.10)

Log-rank p-value: 0.194

*Poisson confidence intervals


Standard	1642	1636	1634	1631	1627
0/1-Hour	1646	1640	1631	1627	1623



0/1-HOUR PROTOCOL PERFORMANCE

Death or MI within 30 days

0/1-Hour
1 %



*Basis for DSMB Recommendation






CUMULATIVE DISTRIBUTION OF TIME

First 12 hrs

ALL
PATIENTS


Standard
0/1-Hour

Proportion of
Participants



Hours in ED

≤ 29 ng/L
TROPONIN T




Discharged from the ED




CARDIAC TESTS WITHIN 30 DAYS

All participants





**No subsequent
cardiac test**






CARDIAC TESTS WITHIN 30 DAYS ≤ 29 ng/L Troponin T






MYOCARDIAL INFARCTION AND INJURY


All patients



Standard



0/1-Hour



CONCLUSIONS

- ❖ Patients classified as “Rule-out MI” are **safe for early discharge** and have low rate of death or MI within 30 days supporting the **routine implementation of a 0/1-hour hs-cTnT protocol**
- ❖ Implementing high-sensitivity troponin in routine practice **does not appear to “improve” the diagnosis of MI**, although the impact on late outcomes and cost-effectiveness await the 12-month analysis
- ❖ However, use of **invasive coronary investigation is increased** among patients with **newly identified low-concentration** troponin elevations and strategies to mitigate associated cardiac injury may require further refinements in acute coronary syndrome care.

Available online ahead of print now

Circulation

<https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042891>



Acknowledgements

Steering Committee:

Cynthia Papendick,
Andrew Blyth,
Anil Seshadri,
Michael JR Edmonds,
Tom Briffa,
Louise A Cullen
Stephen Quinn,
Jonathan Karnon,
Anthony Chuang,
Adam J Nelson,
Deborah Wright,
John K. French

Flinders Health Systems

Research Group:

Kristina Lambrakis,
Erin Morton,
Matthew Horsfall

Study Coordinators

Data Safety Monitoring Board:

Stephen J. Nicholls (Chair),
Philip G. Aylward,
Matthew Worthley,
Richard Woodman
(statistician)

Clinical Events Committee:

John K French (Chair),
Sheraz Nazir,
Dylan Jones,
Amera Halabi,
Nikhil Pal

National Health & Medical Research Council

Roche Diagnostics:

Gesa Albert

SA Pathology:

Penny Coates,
Fotios Visvardis

Research Governance:

Southern Adelaide Local
Health Network
Central Adelaide Local
Health Network

